spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Low Molecular Weight Heparin 

 HSMN NewsFeed - 7 May 2021
Perosphere Technologies Announces CE-IVD Marking of the Perosphere Technologies PoC Coagulometer System for DOAC and Heparin Testing
Devices Diagnostics Regulatory
 HSMN NewsFeed - 15 Apr 2021
Valeo Pharma Announces Commercial Launch of Redesca(TM) and Redesca HP(TM)
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 9 Dec 2020
Valeo Pharma Announces Health Canada Approval for Redesca(TM) and Redesca Hp(TM)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 13 Aug 2018
New Analysis Identifies Patient Populations With Cancer-associated VTE Who Could Benefit From Treatment With Oral, Once-daily LIXIANA(R) (edoxaban)
Biopharmaceuticals
 HSMN NewsFeed - 2 Apr 2015
Perosphere Receives FDA Fast Track Designation for Investigational Anticoagulant Reversal Agent PER977
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Jun 2014
Eliquis(R) (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 May 2013
PBAC Approves XIFAXAN(R) (Rifaxamin α) 550 mg Cost Effectiveness in Australia
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 25 Oct 2011
Lilly Announces Withdrawal of Xigris(R) Following Recent Clinical Trial Results
Biopharmaceuticals
 HSMN NewsFeed - 17 Nov 2010
PolyMedix Appoints Steffen Helmling, Ph.D. as Vice President of Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jun 2010
CoaguSense Receives FDA Clearance for the CoaguSense Blood Coagulation Testing System for Patient Home Use
Devices Diagnostics Monitoring FDA
 HSMN NewsFeed - 17 Aug 2009
Real-World Study Showed Cost Savings for VTE Prophylaxis with Enoxaparin Compared with Unfractionated Heparin (UFH)
Biopharmaceuticals
 HSMN NewsFeed - 8 May 2009
Archimedes Pharma Announces Ground Breaking Phase III Data Showing NasalFent to be Superior to the Standard of Care for Breakthrough Cancer Pain
Biopharmaceuticals Drug Delivery Oncology
 HSMN NewsFeed - 25 Jul 2008
PolyMedix Appoints Two New Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Mar 2008
Novel Oral Anticoagulant Pradaxa(R) (dabigatran etexilate) Approved by the European Commission
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 11 Feb 2008
Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 29 Jan 2008
PolyMedix Appoints Brian Anderson to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Dec 2007
Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data
Biopharmaceuticals
 HSMN NewsFeed - 15 Nov 2007
PolyMedix Appoints Vice President of Drug Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 May 2007
FDA Approves Lovenox(R) (Enoxaparin Sodium Injection) for the Most Severe Type of Heart Attack
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 2 May 2007
FDA Approves FRAGMIN(R) as First Low-Molecular-Weight Heparin for Extended Treatment to Reduce the Recurrence of Blood Clots in Patients with Cancer
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Apr 2007
The Lancet Publishes PREVAIL Study Results Showing Lovenox(R) Superiority Over Unfractionated Heparin for Reducing the Risk of Venous ThromboEmbolism in Patients With Acute Ischemic Stroke
Biopharmaceuticals
 HSMN NewsFeed - 25 Mar 2007
Data Shows That Omission of Venous Thromboembolism (VTE) Prophylaxis in Hospitalized Medical Patients Is Frequent and Leads to Higher Risk of Deep-Vein Thrombosis (DVT)
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 7 Feb 2007
FDA Grants Priority Review to Lovenox(R) (Enoxaparin Sodium Injection) Supplemental New Drug Application (sNDA) for Acute Heart Attack
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 12 Dec 2006
New Study Shows Clexane(R) / Lovenox(R) (Enoxaparin Sodium Injection) is More Effective Than Unfractionated Heparin (UFH) for Preventing the Risk of Venous Thromboembolism (VTE) in Patients With Acute Ischemic Stroke
Biopharmaceuticals
 HSMN NewsFeed - 12 Dec 2006
New Study Shows Lovenox(R) (Enoxaparin Sodium Injection) Is More Effective Than Unfractionated Heparin (UFH) for Lowering the Risk of Venous Thromboembolism (VTE) in Patients With Acute Ischemic Stroke
Biopharmaceuticals
 HSMN NewsFeed - 11 Dec 2006
Positive Phase 3 Results for New Fixed Oral Dose Anticoagulant Presented at 48th Annual Meeting of the American Society of Hematology
Biopharmaceuticals
 HSMN NewsFeed - 2 Jun 2006
ATryn(R) Receives CHMP Recommendation to Grant Market Authorization
Biopharmaceuticals Regulatory
Return to NewsFeed  

 Additional items found! 21

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 21 additional stories matching:
Low Molecular Weight Heparin
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.